P108 - PREVALENCE OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ITS CORRELATION WITH BIOCHEMICAL AND ANTHROPOMETRIC MARKERS IN A PRIVATE HOSPITAL POPULATION IN LEÓN, GUANAJUATO, MEXICO.

Linked sessions

P108

PREVALENCE OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ITS CORRELATION WITH BIOCHEMICAL AND ANTHROPOMETRIC MARKERS IN A PRIVATE HOSPITAL POPULATION IN LEÓN, GUANAJUATO, MEXICO.

Y. D. C. Méndez-Romero1,2,3, P. C. Mojica-Medina3, C. García-Vargas2,3,4,*, M. Rodríguez-Gil2,3,4, A. Lozornio-Jimenez de la Rosa2,4, L. M. Romero Manrique2,5, R. D. C. Castillo-Valenzuela 6, A. N. Mendoza-Hernández2

1Hospital Aranda de la Parra, 2Colegio Mexicano de Nutrición Clínica y Terapia Nutricional, 3Universidad del Valle de Atemajac, 4Hospital Médica Campestre , 5Universidad Iberoamericana, 6Universidad Virtual del Estado de Guanajuato, León, Mexico

 

Rationale: Metabolic-associated fatty liver disease (MAFLD) is one of the hepatic comorbidities linked to obesity. Some reports suggest a prevalence of up to 62% in the Mexican population.¹,² This study aimed to determine the prevalence of MAFLD in individuals undergoing anthropometric assessments.

Methods: This observational, descriptive, cross-sectional, and retrospective study analyzed the medical records of 403 patients who randomly attended general check-ups at a private hospital in León, Guanajuato. Patients included had a diagnosis of MAFLD confirmed by ultrasound and presented with metabolic comorbidities. Variables assessed included weight, height, body mass index (BMI = weight/height²), body fat percentage (%BF), waist-to-height ratio (WHtR), and visceral adiposity index (VAI). Biochemical markers evaluated were total cholesterol, triglycerides, HDL cholesterol, and liver transaminases. tadistical analyses was performed using the Phyton 3.11/SPSS. The study received ethical approval from the Ethics Committee of Hospital Aranda de la Parra.

Results: MAFLD was identified in 25% of the sample (Figure 1). Demographic characteristics are presented in Table 1. Significant correlations between MAFLD and VAI were observed in the age groups ≥30 to <42 years (Spearman’s rho = 0.253, p<0.003) and ≥42 to <52 years (Spearman’s rho = 0.241, p<0.003). WHtR showed a moderate and significant correlation with MAFLD (Spearman’s rho = 0.42, p<0.001) (Tables 2 and 3).

Image:



 

Conclusion: The prevalence of MAFLD was 25%. A higher VAI was weakly associated with increased MAFLD risk. A higher WHtR was moderately and significantly associated with increased MAFLD risk.

References: 1.-Lazo, M., et al. (2013). AJE; 178 (1):38–45.

2.- Bernal-Reyes, R., et al. (2023). Rev Gastroenterol Mex, 88(3):199–207.

Disclosure of Interest: None declared